Ranolazine - @ - Antianginal Agent- (Oct 2009)
Drug Name:
Ranolazine - @ - Antianginal Agent- (Oct 2009)
List Of Brands:
Indication Type Description:
Drug Interaction:
Drugs that cause QT prolongatione.g quinidine, solatol, thioridazine, ziprasidone Potent or moderately potent CYP3A inhibitors e.g ketoconazole, other azole antifungals, dizepam, verapramil, macrolides, protease inhibitors, grape fruit juice Drugs metabolised by p-glycoproteins e.g digoxin, CYP2D6 e.g. tricyclic antidepressants CYP3A e.g simavastatin Inhibitors of CYP2D6 e.g. paroxetine, p-glycoprotein e.g. ritonovir, cyclosporine
Indication:
New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
1.Ranolazine 1000mg ER tablets 31-10-2009
Addl.Stgth
same as approved
2.Ranolazine ER tablets 750mg 24-04-2010
Addl.stgth
same as approved
Symptomatic treatment of patients with chronic stable angina
Adverse Reaction:
Dizziness, headache, nausea, constipation, Seizures, angioedema, tachycardia, tremors, numbness, haematuria, breathessness, Dry mouth, blurred vision, abdominal pain, weakness, tinnititus Bradycardia, hypotension. Elevation of serum creatinine level.
Contra-Indications:
An acute attack of angina, QT prolongation, Ventricular tachycardia Liver impairment.
Drugs that cause QT prolongation eg. quinidine, salatol, thioridizine, Ziprasidone etc. Potent or moderately potent CYP3A inhibitors e.g ketoconazole, other azole antifungals, Diltiazem, verapramil, macrolides, protease inhibitors, grape fruit juice Severe renal impairment
Special precautions-
Monitor blood pressure QT inteterval, elderly, pregnancy
Lactation - not recommended
Dosages/ Overdosage Etc:
Symptomatic treatment of patients with chronic stable angina
Dosage-
Swallow whole Intially 500mg twice daily, may increase to 1g daily Children- not recommended
Patient Information:
Swallow whole tablet
Pregnancy and lactation:
Not recommended during pregnancy and lactation